ATE360030T1 - Polymorphismen der kationentransporter octn1 und octn2 welche mit entzündlichen darmerkrankungen in zusammenhang stehen - Google Patents

Polymorphismen der kationentransporter octn1 und octn2 welche mit entzündlichen darmerkrankungen in zusammenhang stehen

Info

Publication number
ATE360030T1
ATE360030T1 AT02781695T AT02781695T ATE360030T1 AT E360030 T1 ATE360030 T1 AT E360030T1 AT 02781695 T AT02781695 T AT 02781695T AT 02781695 T AT02781695 T AT 02781695T AT E360030 T1 ATE360030 T1 AT E360030T1
Authority
AT
Austria
Prior art keywords
mutations
inflammatory bowel
provides
transcription
octn2
Prior art date
Application number
AT02781695T
Other languages
English (en)
Inventor
Vanya D Peltekova
Richard F Wintle
Laurence A Rubin
George-Hyslop Peter H St
Katherine A Siminovitch
Original Assignee
Ellipsis Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ellipsis Biotherapeutics Corp filed Critical Ellipsis Biotherapeutics Corp
Application granted granted Critical
Publication of ATE360030T1 publication Critical patent/ATE360030T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02781695T 2001-12-21 2002-12-20 Polymorphismen der kationentransporter octn1 und octn2 welche mit entzündlichen darmerkrankungen in zusammenhang stehen ATE360030T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34333801P 2001-12-21 2001-12-21
US36271702P 2002-03-08 2002-03-08
US36270002P 2002-03-08 2002-03-08
US42752902P 2002-11-19 2002-11-19

Publications (1)

Publication Number Publication Date
ATE360030T1 true ATE360030T1 (de) 2007-05-15

Family

ID=32966684

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02781695T ATE360030T1 (de) 2001-12-21 2002-12-20 Polymorphismen der kationentransporter octn1 und octn2 welche mit entzündlichen darmerkrankungen in zusammenhang stehen

Country Status (5)

Country Link
US (2) US20040197777A1 (de)
EP (1) EP1470156B1 (de)
JP (1) JP2005526491A (de)
AT (1) ATE360030T1 (de)
DE (1) DE60219692T2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1761784B1 (de) * 2004-05-24 2016-10-26 Universität Zu Köln Identifizierung des ergothionein-transporters und therapeutische verwendungen davon
WO2009114756A2 (en) * 2008-03-14 2009-09-17 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome
KR101741596B1 (ko) 2014-12-30 2017-05-31 이화여자대학교 산학협력단 Octn1 프로모터 내 단일염기다형성 및 이의 용도
JP6513112B2 (ja) * 2017-02-23 2019-05-15 本田技研工業株式会社 動力伝達装置及び動力伝達装置の潤滑構造

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219727A (en) * 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
JP3778545B2 (ja) * 1997-09-08 2006-05-24 中外製薬株式会社 トランスポーター遺伝子
US5969123A (en) * 1998-03-06 1999-10-19 Millennium Biotherapeutics, Inc. Nucleic acid molecules derived from a brain tissue library
US20030204075A9 (en) * 1999-08-09 2003-10-30 The Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome

Also Published As

Publication number Publication date
JP2005526491A (ja) 2005-09-08
EP1470156A2 (de) 2004-10-27
DE60219692T2 (de) 2007-12-27
EP1470156B1 (de) 2007-04-18
DE60219692D1 (de) 2007-05-31
US20060105381A1 (en) 2006-05-18
US20040197777A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
Jia et al. Neuroinflammation in Huntington’s disease: From animal models to clinical therapeutics
Li et al. Targeting RIPK1 kinase for modulating inflammation in human diseases
DeMars et al. Neuroprotective effects of targeting BET proteins for degradation with dBET1 in aged mice subjected to ischemic stroke
BRPI0716088A8 (pt) anticorpo isolado, composição, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para produzir um anticorpo, hibridoma, métodos para aliviar um ou mais sintomas de doença, e para diminuir ou inibir a ligação de hlight a hvem, ltbr, dcr3 ou qualquer combinação dos mesmos, e para diminuir ou inibir a secreção de ccl20, il-8, rantes ou qualquer combinação dos mesmos, e, kit
DE69422726D1 (de) Peptidverbindungen und ihre therapeutische verwendung als inhibitoren von metalloproteinasen
WO2004000997A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
BRPI0609020A2 (pt) polipeptídeo, proteína de fusão, molécula de ácido nucleido purificada, vetor, célula hospedeira, ligando, composto, método para diagnosticar uma doença em um paciente, uso de um polipeptídeo, composição farmacêutica, composição de vacina, métodos para monitorar o tratamento terapêutico de doença em paciente e para a identificação de um composto que é eficaz no tratamento e/ou diagnóstico de doença, kit, animal não humano transgênico ou knockout, método para a triagem quanto a um composto eficaz para tratar doença, e, método para selecionar compostos biologicamente ativos"
BR0309638A (pt) Polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, ligando, composto, método de diagnóstico de uma doença em um paciente, uso de um polipeptìdeo, composição farmacêutica, composição de vacina, métodos de tratamento de uma doença em um paciente, de monitoração do tratamento terapêutico de doença em um paciente, e de identificação de um composto que é eficaz no tratamento e/ou no diagnóstico de doença, kit, animal não humano knockout ou transgênico, e, método para a seleção de um composto eficaz para o tratamento de doença
BR0009805A (pt) Mutações de enos úteis para terapia genética e rastreamento terapêutico
Paronis et al. Cilostazol mediates immune responses and affects angiogenesis during the acute phase of hind limb ischemia in a mouse model
ATE360030T1 (de) Polymorphismen der kationentransporter octn1 und octn2 welche mit entzündlichen darmerkrankungen in zusammenhang stehen
WO2003054011A3 (en) Polymorphisms of the octn1 and octn2 cation transporters associated with inflammatory bowel disease
Zheng et al. Discovery of sinomenine derivatives inhibiting macrophage polarization against rheumatoid arthritis through selectively targeting heme oxygenase-1
WO2002079398A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
BRPI0409802A (pt) método para identificar um membro da famìlia secfam3, polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, ligando, composto, método para diagnosticar uma doença em um paciente, uso de um polìpeptìdeo, composição farmacêutica, composição de vacina, métodos para tratar uma doença em um paciente, para monitorar o tratamento terapêutico de doença em um paciente, e para a identificação de um composto que é eficaz no tratamento e/ou diagnóstico de doença, kit, animal não humano transgênico ou silenciado, e, método para triar para um composto eficaz para tratar doença
WO2004050860A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
DK1261712T3 (da) Proteiner benævnt FXTRC og nucleinsyrer kodende for samme
WO2003078572A3 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
WO2002099116A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003040329A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
BRPI0416507A (pt) polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, uso de um polipeptìdeo, uma molécula de ácido nucleico, um vetor, ou uma célula hospedeira, composição farmacêutica, uso de um antagonista de citocina ou um agente anti-inflamatório, uso de polipeptìdeo,uma molécula de ácido nucleico, um vetor, ou uma célula hospedeira,e um antagonista de citocina ou um agente anti-inflamatório, método de tratamento de uma doença em um paciente, e para a identificação de um composto e, animal transgênico não humano
Wang et al. Mouse Resistin (mRetn): cloning, expression and purification in Escherichia coli and the potential regulative effects on murine bone marrow hematopoiesis
WO2004050858A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
WO2003066877A3 (en) Compositions and methods relating to hepatic specific genes and proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties